GABA-Enhancing Neurosteroids as New Treatments in Psychiatry

This activity is part of a series

Faculty

Charles F. Zorumski, MD
Samuel B. Guze Professor and Head of Psychiatry, Professor of Neuroscience
Director, Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO
Charles F. Zorumski, MD

Dr. Zorumski is the Samuel B. Guze (Goo-ZAY) Professor and Head of the Department of Psychiatry and Professor of Neuroscience at Washington University School of Medicine (WUSM) in St. Louis. Dr. Zorumski is also Psychiatrist-in-Chief at Barnes- Jewish Hospital and Director of the Taylor Family Institute for Innovative Psychiatric Research. Dr. Zorumski’s laboratory studies synaptic transmission in the hippocampus. His studies focus on short- and long-term modulation of the glutamate and GABA neurotransmitter systems, with emphasis on how these transmitter systems participate in memory and neuropsychiatric disorders. A long-standing interest concerns the mechanisms by which neurosteroids and oxysterols modulate GABA and glutamate receptors. Clinically, Dr. Zorumski is interested in the treatment of refractory mood disorders. He has published more than 340 scientific papers, five books and holds five patents. His work has been funded by the National Institutes of Health since 1987.

Dr. Zorumski was named Head of the Washington University Department of Psychiatry in 1997 and Samuel B. Guze Professor in 1998. Since 1997, he has served on the Steering Committees of the McDonnell Center for Cellular and Molecular Neurobiology and the McDonnell Center for Systems Neuroscience and was Director of the Center for Cellular and Molecular Neurobiology from 2002 to 2013. Dr. Zorumski was named founding Director of the Taylor Family Institute in 2012. In 2015, Dr. Zorumski became Chair of the Center for Brain Research in Mood Disorders. He serves on the Editorial Boards of JAMA Psychiatry and Cerebrum and served on the Board of Scientific Counselors for the NIMH Intramural Research Program from 2009 to 2013. Dr. Zorumski is a distinguished fellow of the American Psychiatric Association, and a fellow of the American College of Neuropsychopharmacology and the American Psychopathological Association. He was elected to the National Academy of Medicine (Institute of Medicine) in 2012 and has previously served on the Academy’s Forum on Neuroscience and Nervous System Disorders. Since 2011, he has also served on the Scientific Advisory Board of Sage Therapeutics, a publicly-traded company developing neurosteroids and oxysterols as treatments for neuropsychiatric illnesses.

Statement of Need

This video is a replay of a plenary session from the 12th Annual Chair Summit Master Class for Neuroscience Professional Development held in Las Vegas, NV from February 27-29, 2020.

Learning Objectives

At the end of this CME/CE activity, participants should be able to evaluate the latest clinical evidence on the safety and efficacy of neurosteroids in treating mood disorders.

Financial Support

This activity is supported by CME Outfitters.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals with an interest in psychiatry, neurology, and the neurosciences.

Credit Information

Physicians (ACCME)

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE)

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Zorumski reports that he receives grant support from the Bantly Foundation; National Institute of Mental Health (NIMH); and Sage Therapeutics, Inc. He is a consultant for Sage Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Sage Therapeutics, Inc. He holds patents for Neurosteroid analogs & GABA receptors; redox reagents & T-channels; and oxysterols as neuroprotectants.


Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

While credit is no longer available, the Annual Chair Summit Master Class for Neuroscience Professional Development has made recordings available for a fee of $5 each, or $50 for the complete set of sessions.


Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 

CHV-108-031621-00

GABA-Enhancing Neurosteroids as New Treatments in Psychiatry
Event Date: 03/16/2021